PrEPVacc (@PrEPVacc) header
PrEPVacc (@PrEPVacc) profile picture

African-led, European-supported HIV prevention project running in four countries in East and Southern Africa from 2018 to 2024

East and Southern Africa
Joined January 2018
Photo by PrEPVacc (@PrEPVacc)Photo by PrEPVacc (@PrEPVacc)Photo by PrEPVacc (@PrEPVacc)Photo by PrEPVacc (@PrEPVacc)Photo by PrEPVacc (@PrEPVacc)Photo by PrEPVacc (@PrEPVacc)Photo by PrEPVacc (@PrEPVacc)Photo by PrEPVacc (@PrEPVacc)Photo by PrEPVacc (@PrEPVacc)Photo by PrEPVacc (@PrEPVacc)
Experts in virology, immunology and epidemiological research at the Unit have shared key insights from notable HIV studies on various platforms at the @AIDS_conference. We’re very honored to contribute to global discussions to improve health. #AIDS2024
3
14
737
“Our participants’ dedication to this study has been exemplary. They and their communities should be very proud of their efforts and their important contributions to the global effort to prevent HIV.” @PrEPVacc Trial Director, Dr Eugene Ruzagira, @MRC_Uganda
4
5
443
“Community engagement is imperative in all phases of research. In @PrEPVacc there have been positive community interactions so that people were well informed on developments, expectations, and transparency,” Xoliswa Nomvungu, Community Working Group at @MRCza Verulam, Durban
1
5
104
During the @PrEPVacc vaccine trial, counselling, promotion and provision of #PrEP were emphasised at every visit to all participants, with active follow-up regarding use. The study will now follow all participants for at least two years.
1
4
59
"The positive news for our communities is that repeated risk reduction counselling and use of proven HIV prevention tools helps people navigate their risks better."
1
1
3
265
"The number of new infections has fallen throughout the six years we have been monitoring the HIV incidence in each study community," @PrEPVacc Trial Director, Dr Eugene Ruzagira, @MRC_Uganda
1
3
209
Happy #InternationalWomensDay to the incredible women at @MRC_Uganda who inspire and lead with grace and strength. Your contributions to the Unit not only impact Uganda but ripple across the globe. We celebrate you! #InspireInclusion #WD2024
10
47
1,702
Today, we celebrate Dr. Sylvia Kusemererwa, a dedicated female scientist leading groundbreaking research at the Unit. She has coordinated clinical trials that have impacted policy change globally. Read more about her: linkedin.com/feed/update/urn… #WomenLedScience #CelebratingWomen
2
5
29
1,368
PrEPVacc retweeted
Researchers from SAMRCs #HIV and Other Infectious Diseases Research Unit spoke to 150 participants from the Verulam site in Durban thanking them for their contribution in the PrEPVacc Trial update.
1
5
599
PrEPVacc retweeted
Xoliswa is a nurse, an active volunteer & Community Working Group Member. Here she expresses her appreciation to SAMRC researchers for sharing the PrEPVacc study update at a Media Café hosted by AVAC. In a panel with Dr Ruzagira (UGA), Dr Kansiime (UGA) & Prof McCormack (UK).
2
3
503
[ON AIR] 🎧 @khumbza on #AfrikaTonight 🚨PrEPVacc recently announced that vaccinations have been stopped in its HIV Phase 2 prevention study. Prof. Glenda Grey-SAMRC President & CEO joins us to discuss this @SABCPlus app | DSTV 802 | Stream: bit.ly/SoundaAfrica
2
2
195
PrEPVacc retweeted
Neetha Morar, Research Manager, together with Sibusio Nhleko shared key messages to share with the community which included advocating for uptake of current prevention methods. Xoliswa Nomvungu, chair of the CWG, thanked the SAMRC, HIDRU (samrc.ac.za/research/intramu…) team.
1
3
316
PrEPVacc retweeted
Dr Nishanta Singh, PrEPVacc Principal Investigator (Verulam site), explained the study update to the community working group (CWG) members on the 5th December 2023, prior to public release.
1
2
4
615
PrEPVacc retweeted
Experimental HIV vaccine regimens likely to be ineffective in preventing HIV acquisition, @PrEPVacc study reports samrc.ac.za/press-releases/e…
1
4
1
2
1,547
PrEPVacc retweeted
Replying to @PrEPVacc
@PrEPVacc announced that vaccinations have been stopped in its HIV Phase 2 prevention study of experimental vaccine regimens running in East and Southern Africa due to lack of demonstrated efficacy in preventing HIV acquisition. samrc.ac.za/press-releases/s…
1
2
109
PrEPVacc retweeted
Today the @PrEPVacc trial team announced at #ICASA2023 that they were stopping vaccinations after it was determined there was little chance the vaccines could stop HIV acquisition. Read AVAC's full response of the trial ending early here: avac.org/blog/the-search-for…
5
5
442
Prepvacc HIV prevention study halts vaccinations due to inefficacy in preventing HIV acquisition #NTVNews More Details | tinyurl.com/yc58ujjf?utm_med…
1
15
2,757